XBIT

XBiotech Inc.

$1.97

3.14%
SectorHealthcareIndustryBiotechnologyCountryUnited States

XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Source: Yahoo Finance
Q-Score48/ 100
Market Cap$60.1M
P/E—
Dividend Yield0.00%
52-Week Range—
Next Earnings—
Analysts—
Beta1.05
AI summary

Price & performance

1M-14.0%
3M-13.6%
YTD-17.2%
1Y-19.6%
52-week range—
Beta1.05
Full chart and returns against a benchmark

Q-Score

48/ 100

Quality against peers; 50 is the peer median.

Growth42
Risk57
Performance39
Valuation49
Profitability46
Leverage78
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue—
Net income-$45.5M
Net margin—
Historical fundamentals

Revenue exposure

Regions, segments, customers and suppliers

Valuation

XBITIndustryP/E—89.69P/S—11.88EV/EBITDA—67.10P/B0.476.22PEG—4.02
Dividend yield0.00%
Every valuation metric